How IgG Subclass and PTMs Impact IgG Activity

A paper published recently in Nature Immunology, sheds light on the effects of post-translational modifications and subclass on immunoglobulin G (IgG) activity. According to first author Prof. Dr. Falk Nimmerjahn from Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU),these insights could be used to optimize therapeutic antibody development.

IgG, composed of proteins arranged in a Y-shaped structure, plays a crucial role in the immune response. The top branches of the Y shape contain structures that match with various pathogens, acting like a key in a lock. After an infection, IgG remains in the body and can rapidly respond to reinfection. When the matching key fits the lock, IgG attaches to the pathogen and marks it for elimination by other immune cells.

Prof. Nimmerjahn's research explores the role of the backbone of IgG in the later stages of the immune response. Macrophages, killer cells, and granulocytes work together to combat the infection. Granulocytes sacrifice themselves by releasing their sticky genetic material, to which harmful bacteria identified by IgG attach. Macrophages then consume the marked bacteria. However, macrophages can cause collateral damage due to their aggressive behavior, releasing potentially harmful substances.

Fine-tuning the immune response involves posttranslational modifications in the backbone of IgG, such as attaching sugar molecules. These modifications play a crucial role in modulating the immune reaction. Insufficient modifications can lead to a more severe immune response, which can be dangerous, especially when tissues are already damaged. Understanding the control mechanisms of antibody tuning is essential for improving antibody therapy in tumor treatment and autoimmune diseases, ensuring patients' tolerance and safety.

By gaining precise knowledge of antibody tuning within the immune response, researchers can optimize the therapeutic use of antibodies. This research opens up avenues for enhancing the effectiveness of antibody-based treatments, mitigating harmful immune reactions, and increasing patients' tolerance, ultimately improving outcomes in various medical conditions.